AIM:To clarify the effects of anti-hypertensive drugs on esophageal contraction and determine their possi-ble relationship with gastro-esophageal reflux disease.METHODS:Thirteen healthy male volunteers were enrolled. ...AIM:To clarify the effects of anti-hypertensive drugs on esophageal contraction and determine their possi-ble relationship with gastro-esophageal reflux disease.METHODS:Thirteen healthy male volunteers were enrolled. Esophageal body peristaltic contractions and lower esophageal sphincter (LES) pressure were measured using high resolution manometry. All subjects were randomly examined on four separate occasions following administrations of nifedipine,losartan,and atenolol,as well as without any drug administration.RESULTS:Peristaltic contractions by the esophageal body were separated into three segments by two troughs. The peak peristaltic pressures in the mid and lower segments of the esophageal body under atenolol administration were signifi cantly higher than those without medication in a supine position. On the other hand,peristaltic pressures under nifedipine administration were lower than those observed without drug ad-ministration. Losartan did not change esophageal body peristalsis. Atenolol elevated LES pressure and slowed peristaltic wave transition,while the effects of nifedip-ine were the opposite. CONCLUSION:Among the anti-hypertensive drugs tested,atenolol enhanced esophageal motor activity,which was in contrast to nifedipine.展开更多
Chronic kidney disease （CKD） is a significant interactive disease in patients with diabetes, hypertension, and cardiovascular disease with major morbidity consequences and high costs to the healthcare system. The pr...Chronic kidney disease （CKD） is a significant interactive disease in patients with diabetes, hypertension, and cardiovascular disease with major morbidity consequences and high costs to the healthcare system. The prevalence of end stage renal disease （ESRD）, a f＇mal outcome of CKD, has increased progressively in the past decades in both developing and developed countries. It is now appreciated that the majority of patients with CKD have a chronic decline of renal function over years before renal replacement therapy is required. This non-specific process continues even when the initial insult is no longer present and has been called progression of CKD.展开更多
基金Supported by The Grants-in-Aid from Science Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan, No. 19590724
文摘AIM:To clarify the effects of anti-hypertensive drugs on esophageal contraction and determine their possi-ble relationship with gastro-esophageal reflux disease.METHODS:Thirteen healthy male volunteers were enrolled. Esophageal body peristaltic contractions and lower esophageal sphincter (LES) pressure were measured using high resolution manometry. All subjects were randomly examined on four separate occasions following administrations of nifedipine,losartan,and atenolol,as well as without any drug administration.RESULTS:Peristaltic contractions by the esophageal body were separated into three segments by two troughs. The peak peristaltic pressures in the mid and lower segments of the esophageal body under atenolol administration were signifi cantly higher than those without medication in a supine position. On the other hand,peristaltic pressures under nifedipine administration were lower than those observed without drug ad-ministration. Losartan did not change esophageal body peristalsis. Atenolol elevated LES pressure and slowed peristaltic wave transition,while the effects of nifedip-ine were the opposite. CONCLUSION:Among the anti-hypertensive drugs tested,atenolol enhanced esophageal motor activity,which was in contrast to nifedipine.
基金This work was partly supported by the National 973 Program （No. 2006CB03904） and the National Natural Science Foundation of China （No. 30330300）.
文摘Chronic kidney disease （CKD） is a significant interactive disease in patients with diabetes, hypertension, and cardiovascular disease with major morbidity consequences and high costs to the healthcare system. The prevalence of end stage renal disease （ESRD）, a f＇mal outcome of CKD, has increased progressively in the past decades in both developing and developed countries. It is now appreciated that the majority of patients with CKD have a chronic decline of renal function over years before renal replacement therapy is required. This non-specific process continues even when the initial insult is no longer present and has been called progression of CKD.
